This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


OSE Immunotherapeutics

Drug Names(s): FR-104, FR 104

Description: FR104 is a pegylated Fab’ fragment of a humanized monovalent anti-CD28 antibody, which neutralizes CD28 interaction with CD80/CD86 ligands (and also with CD275/ICOS-L). Due to its monovalent form, FR104 blocks CD28-CD80/86 interactions without activating T cells16. Unlike CD80/86 antagonists, FR104 does not prevent the powerful regulatory CTLA4-CD80/86 interactions, essential for the suppressive activity of T regulatory cells (Treg) and even more reinforces the CTLA4-dependent suppressive activity of Treg while inhibiting Effector T cells (Teff). FR104 is pegylated on its C-terminal cysteine, inducing a 10 fold increase of its serum half live.

Deal Structure: Effimune and Janssen
In October 2013, Effimune announced a global option and license agreement with Janssen Biotech. The collaboration between Effimune, the London Innovation Centre of Johnson & Johnson Innovation and the Janssen Immunology Therapeutic Area is focused on the development and commercialization of FR104, a monoclonal antibody fragment in preclinical development for the treatment of immune- mediated disorders. Additional financial details were not disclosed.

OSE and Effimune
In February 2016, OSE Pharma and Effimune announced the signing of a proposed merger agreement. The Boards of Directors of both OSE Pharma and Effimune have approved the proposed terms of the merger, which will be submitted for approval to the shareholders of the two companies during Extraordinary General Meetings. The merger will result in the shareholders of OSE Pharma owning approximately 71% of the capital of the merged entity and the shareholders of Effimune, 29%....See full deal structure in Biomedtracker

Partners: Johnson & Johnson

FR104 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug